A recent peer-reviewed study published in the American Journal of Endocannabinoid Medicine suggests that medical cannabis could potentially play a role in managing fibromyalgia and its associated symptoms of depression and anxiety.
The study, conducted by researchers at Harvest Medicine, a subsidiary of MediPharm Labs Corp (MEDIF, +9.11%), involved more than 800 patients. The results showed that three-fourths of the participants reported a significant decrease in their self-reported illness severity after using medical cannabis.
Fibromyalgia is a chronic condition that affects approximately 4 million adults in the United States. It is characterized by musculoskeletal pain, fatigue, and mood issues.
The majority of patients in the study used CBD oil, with about half of those suffering from severe anxiety or depression experiencing a reduction in their symptoms.
MediPharm Labs Corp specializes in the development and manufacturing of cannabis concentrates and active pharmaceutical ingredients.
As of Thursday’s premarket, MediPharm stock remained unchanged, but it has seen a 15.6% increase in value since the beginning of the year. In comparison, the S&P 500 has gained 17.6% over the same period.
Overall, this study provides promising evidence for the potential benefits of medical cannabis in managing fibromyalgia and related symptoms. Further research is needed to explore this therapeutic option fully.
